Horizon Therapeutics plc

Biopharmaceutical company that discovers, develops, and commercializes medicines addressing critical needs in rare diseases, immunology, and specialty areas like thyroid eye disease (Tepezza) and gout (Krystexxa). HQ Dublin, Ireland; acquired by Amgen for $27.8B in Oct 2023.